Stroma-derived factor 1alpha induces a selective inhibition of human erythroid development via the functional upregulation of Fas/CD95 ligand.
CXC chemokine receptor 4 (CXCR4), the high-affinity receptor for stroma-derived factor 1alpha (SDF-1alpha), shows distinct patterns of expression in human CD34+ haematopoietic progenitor cells induced to differentiate in vitro along the granulocytic and erythroid lineages. In serum-free liquid cultures supplemented with stem cell factor (SCF), interleukin 3 (IL-3) and granulocyte colony-stimulating factor, the expression of surface CXCR4 progressively increased in cells differentiating along the granulocytic lineage. The addition in culture of 200 ng/ml of SDF-1alpha, a concentration which maximally activated intracellular Ca2+ flux, only modestly affected the expression levels of CD15 and CD11b granulocytic antigens, as well as the total number of viable cells. On the other hand, in liquid cultures supplemented with SCF, IL-3 and erythropoietin, SDF-1alpha induced the downregulation of glycophorin A erythroid antigen, accompanied by a progressive decline in the number of viable erythroblasts. Moreover, in semisolid assays, SDF-1alpha significantly reduced the number of plurifocal erythroid colonies (erythroid blast-forming units; BFU-E), whereas it did not affect granulocyte-macrophage colony-forming units (CFU-GM). We also demonstrated that the inhibitory effect of SDF-1alpha on glycophorin A+ erythroid cell development was mediated by the functional upregulation of CD95L in erythroid cultures. These data indicate that SDF-1alpha plays a role as a negative regulator of erythropoiesis.
Gibellini
D
D
Department of Clinical and Experimental Medicine, Microbiology Section, University of Bologna, Bologna, Italy.
Bassini
A
A
Re
M C
MC
Ponti
C
C
Miscia
S
S
Gonelli
A
A
La Placa
M
M
Zauli
G
G
D018952:Antigens, CD34; D002118:Calcium / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000494:pharmacology*; D003864:Depression, Chemical; D004920:Erythropoiesis / Q000187:drug effects*; D053222:Fas Ligand Protein; D005312:Fetal Blood / Q000166:cytology; D006021:Glycophorins / Q000378:metabolism; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D008562:Membrane Glycoproteins / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism*; D019089:Stem Cell Factor / Q000494:pharmacology
D018952:Antigens, CD34; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D006021:Glycophorins; D007377:Interleukin-3; D008562:Membrane Glycoproteins; D019718:Receptors, CXCR4; D019089:Stem Cell Factor; D016179:Granulocyte Colony-Stimulating Factor; D002118:Calcium